Medical Developments International Ltd crashes 5.4% on report

Medical Developments International Ltd (ASX:MVP) disappoints shareholders.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price has fallen by 5.4% after investors reacted to its reported.

Here are some of the highlights for the half-year to 31 December 2017 compared to the prior corresponding period:

  • Revenue decreased by 2.6% to $8 million
  • Gross margin increased to 72% from 69%
  • Earnings before interest, tax, depreciation and amortisation (EBITDA) decreased by 26% to $872 million
  • Net profit after tax (NPAT) decreased by 69% to $127 million
  • Dividend maintained at 2 cents per share

The company said that the building blocks are now in place for sales growth as we commence sales into all 22 new European countries, Mexico, Canada, Saudi Arabia and Hong Kong. It is also confident about growing its respiratory device sales in the USA, Europe and elsewhere.

Medical Developments pointed to 115% growth of respiratory devices in the USA and sales growth of 21% in the UK and Europe as signs of the company's progress.

It has made 'good progress' with its development of the 'Breath-A-Tech' anti-static range of devices and the CSIRO project is ahead of expectations with small scale production for two drugs.

Outlook

Over the next few years the global market approvals and indications are expected to deliver strong growth. It says that it will continue its global expansion and in-particular build the USA business. It expects to deliver new partnership deals and expand the product offering, which should grow sales significantly.

The company believes that Penthrox could be approved by the Food Drug Administration for sale in the USA during 2020. It is in talks with several interested parties to sell Penthrox in the USA.

Foolish takeaway

It's no surprise to me that the share price fell today, as even after the drop it's trading at 122x FY18's estimated earnings and it will have to have a very good second half to deliver on those expected earnings. It may have an exciting long-term future, but it's hard to justify today's value when the profit and revenue went backwards in this report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »